Cymbalta
E133649
Cymbalta is a prescription antidepressant medication (duloxetine) commonly used to treat major depressive disorder, generalized anxiety disorder, and certain types of chronic pain.
All labels observed (2)
| Label | Occurrences |
|---|---|
| duloxetine | 2 |
| Cymbalta canonical | 1 |
How this entity was disambiguated
This entity first appeared as the object of triple T1168572 — resolving that mention is where its identity was fixed. The disambiguator weighed these candidate entities and picked the highlighted one (or “None”, minting a new entity). This is how homonymy is resolved: the same surface form can point to different entities.
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: Cymbalta Context triple: [Eli Lilly and Company, notableProduct, Cymbalta]
-
A.
Anpezan
Anpezan is a regional dialect of the Ladin language spoken in parts of the Dolomite area of northern Italy.
-
B.
Darzalex
Darzalex is a monoclonal antibody drug (daratumumab) used primarily in the treatment of multiple myeloma.
-
C.
Denesuline
Denesuline are a First Nations people of the larger Dene cultural and linguistic group, traditionally inhabiting subarctic regions of northern Canada.
-
D.
Vumerity
Vumerity is an oral prescription medication used to treat relapsing forms of multiple sclerosis in adults.
-
E.
rivastigmine
Rivastigmine is a cholinesterase inhibitor medication used to manage symptoms of mild to moderate dementia, particularly in Alzheimer's and Parkinson's disease.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: Cymbalta Target entity description: Cymbalta is a prescription antidepressant medication (duloxetine) commonly used to treat major depressive disorder, generalized anxiety disorder, and certain types of chronic pain.
-
A.
Anpezan
Anpezan is a regional dialect of the Ladin language spoken in parts of the Dolomite area of northern Italy.
-
B.
Darzalex
Darzalex is a monoclonal antibody drug (daratumumab) used primarily in the treatment of multiple myeloma.
-
C.
Denesuline
Denesuline are a First Nations people of the larger Dene cultural and linguistic group, traditionally inhabiting subarctic regions of northern Canada.
-
D.
Vumerity
Vumerity is an oral prescription medication used to treat relapsing forms of multiple sclerosis in adults.
-
E.
rivastigmine
Rivastigmine is a cholinesterase inhibitor medication used to manage symptoms of mild to moderate dementia, particularly in Alzheimer's and Parkinson's disease.
- F. None of above. chosen
Statements (49)
| Predicate | Object |
|---|---|
| instanceOf |
antidepressant
ⓘ
pharmaceutical drug ⓘ serotonin–norepinephrine reuptake inhibitor ⓘ |
| affects |
norepinephrine reuptake
ⓘ
serotonin reuptake ⓘ |
| hasActiveIngredient | duloxetine hydrochloride ⓘ |
| hasATCCode | N06AX21 ⓘ |
| hasBlackBoxWarning | increased risk of suicidal thoughts and behaviors in children, adolescents, and young adults ⓘ |
| hasCommonSideEffect |
constipation
ⓘ
decreased appetite ⓘ dizziness ⓘ dry mouth ⓘ fatigue ⓘ hyperhidrosis ⓘ insomnia ⓘ nausea ⓘ somnolence ⓘ |
| hasContraindication |
concomitant use with MAO inhibitors
ⓘ
uncontrolled narrow-angle glaucoma ⓘ |
| hasDosageForm | delayed-release capsule ⓘ |
| hasDrugClass | SNRI ⓘ |
| hasEliminationHalfLife | about 12 hours ⓘ |
| hasFirstApprovalYearUS | 2004 ⓘ |
| hasGenericName |
Cymbalta
self-linksurface differs
ⓘ
surface form:
duloxetine
|
| hasIndicationPopulation | adults ⓘ |
| hasLegalStatusEU | prescription only ⓘ |
| hasLegalStatusUS | prescription only ⓘ |
| hasManufacturer | Eli Lilly and Company ⓘ |
| hasPregnancyCategoryUS | C ⓘ |
| hasRouteOfAdministration | oral ⓘ |
| hasSeriousRisk |
abnormal bleeding
ⓘ
angle-closure glaucoma ⓘ hepatotoxicity ⓘ hyponatremia ⓘ orthostatic hypotension ⓘ serotonin syndrome ⓘ |
| hasWithdrawalRisk | discontinuation syndrome ⓘ |
| isApprovedBy |
Food and Drug Administration
ⓘ
surface form:
U.S. Food and Drug Administration
|
| isBrandOf |
Cymbalta
self-linksurface differs
ⓘ
surface form:
duloxetine
|
| isMetabolizedBy |
CYP1A2
ⓘ
CYP2D6 ⓘ |
| isPrescriptionOnly | true ⓘ |
| requiresCautionIn | severe renal impairment ⓘ |
| requiresDoseAdjustmentIn | hepatic impairment ⓘ |
| treats |
chronic musculoskeletal pain
ⓘ
diabetic peripheral neuropathic pain ⓘ fibromyalgia ⓘ generalized anxiety disorder ⓘ major depressive disorder ⓘ |
How these facts were elicited
The pipeline generated the facts above by prompting gpt-5.1 with this entity's name + description and the instruction below.
Instruction
You are a knowledge base construction expert. Given a subject entity and a description of it, return factual statements that you know for the subject as a JSON list of dictionaries(triples), where keys must be "subject", "predicate" and "object". The number of facts may be very high, between 25 to 50 or more, for very popular subjects. For less popular subjects, the number of facts can be very low, like 5 or 10. # Requirements - If you don't know the subject at all, return an empty list. - If the subject is not a named entity, return an empty list. - Include at least one triple where predicate is "instanceOf". - Do not get too wordy. - Separate several objects into multiple triples with one object.
Input
Subject: Cymbalta Description of subject: Cymbalta is a prescription antidepressant medication (duloxetine) commonly used to treat major depressive disorder, generalized anxiety disorder, and certain types of chronic pain.
Referenced by (3)
Full triples — surface form annotated when it differs from this entity's canonical label.
this entity surface form:
duloxetine